Trends in lipid-lowering therapies in acute coronary syndromes after Chinese new insurance policy: a real-world analysis

Abstract Background The Chinese new insurance policy for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), which made it more affordable to patients from January 1, 2022, may change lipid-lowering therapy (LLT) pattern for acute coronary syndromes (ACS), but real-world data is still...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Xin Zhao, Shujing Wu, Zhen Wang, Luning Zhou, Peng Zhang, Huajie Xu, Mengmeng Yu, Zhiyong Qi, Lili Xu, Neng Dai, Hongbo Yang, Yingnan Bai, Bing Fan, Juying Qian, Hongyi Wu, Junbo Ge
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2026-01-01
Saila:	BMC Medicine
Gaiak:	Lipid-lowering therapies Acute coronary syndromes Insurance Proprotein convertase subtilisin/kexin type 9 inhibitors
Sarrera elektronikoa:	https://doi.org/10.1186/s12916-026-04616-2
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!